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Response to the letter to the Editor, BJOG Exchange 
 
Re: Implementation of routine first trimester combined screening for pre-eclampsia: a 
clinical effectiveness study 
 
We would like to thank Professors Wright and Nicolaides for their comments on our clinical 
effectiveness study1 and share their hopes for the wider implementation of a combined 
screening programme for preeclampsia prevention in our public health systems. We agree 
with their emphasis on the importance of accounting for the effect of aspirin when assessing 
predictive performance of the combined screening test for preeclampsia – hence our formal 
acknowledgment about this issue in our paper. We did not perform a similar analysis as the 
journal policy on article word limits precluded such inclusion and because our focus was on 
the effectiveness of the screening programme to reduce the rate of preeclampsia rather than 
the accuracy of the screening test to predict preeclampsia. 
 
Nevertheless, it is reassuring to us to note that the calculations performed by Professor 
Wright support our assertion that routine NHS health systems are able to deliver effective 
screening which has only been previously seen in the context of research efficacy studies or 
randomized controlled trials2,3. Our study illustrates not only the effectiveness of the 
preeclampsia screening programme, but also the ability to provide equity and access to care 
to black and other ethnic minority populations as well as those with social deprivation and 
comorbidities – who are all more likely to suffer from preeclampsia4. We believe that the 
scientific data now overwhelmingly supports the need to re-evaluate current service 
provision for preeclampsia. 
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